Format

Send to

Choose Destination
Brain. 2019 Sep 27. pii: awz277. doi: 10.1093/brain/awz277. [Epub ahead of print]

Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration.

Author information

1
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
2
Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France.
3
Department of Neuroscience, Mayo Clinic, Florida, USA.
4
Health Science Research, Mayo Clinic, Rochester, MN, USA.
5
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
6
Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
7
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Abstract

Over the past decade, the transactive response DNA-binding protein of 43 kDa (TDP-43) has been recognized as a major protein in normal and pathological ageing, increasing the risk of cognitive impairment and dementia. In conditions distinct from the frontotemporal lobar degenerations, TDP-43 appears to progress in a stereotypical pattern. In the present study, we aimed at providing a better understanding of the effects of TDP-43 and other age-related neuropathologies on cross-sectional grey matter volume in a cohort of non-FTLD subjects. We included 407 individuals with an antemortem MRI and post-mortem brain tissue from the Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic Alzheimer's Disease Patient Registry, or the Mayo Clinic Study of Aging. All individuals were assigned pathological stages for TDP-43, tau, amyloid-β, Lewy bodies, argyrophilic grain disease and vascular pathologies. Robust regressions were performed in regions of interest and voxel-wise to explore the relationships between TDP-43 stages and grey matter volume while controlling for other pathologies. Grey matter volumes adjusted for pathological and demographic variables were also computed for each TDP-43-positive case to further characterize the sequential involvement of brain structures associated with TDP-43, irrespective of the TDP-43 staging scheme. Robust regressions showed that the extent of TDP-43 pathology was associated with the extent of grey matter atrophy. Specifically, we found that the volume in medial temporal regions (i.e. amygdala, entorhinal cortex, hippocampus) decreased progressively with advancing TDP-43 stages. Importantly, these effects were of similar magnitude to those related to tau stages. Additional analyses using adjusted grey matter volume demonstrated a sequential pattern of volume loss associated with TDP-43, starting within the medial temporal lobe, followed by early involvement of the temporal pole, and eventually encompassing additional temporal and frontal regions. Altogether, this study demonstrates the major and independent contribution of TDP-43 pathology on neurodegeneration and provides further insight into the regional distribution of TDP-43 in non-FTLD subjects. Along with previous studies, these findings emphasized the importance of targeting TDP-43 in future clinical trials to prevent its detrimental effect on grey matter volume and, eventually, cognition.

KEYWORDS:

TDP-43; neuropathology; radiological-pathological study; tau; β-amyloid

PMID:
31562527
DOI:
10.1093/brain/awz277

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center